6.70
price up icon0.45%   0.03
after-market Handel nachbörslich: 6.70
loading
Schlusskurs vom Vortag:
$6.67
Offen:
$6.64
24-Stunden-Volumen:
717.29K
Relative Volume:
0.37
Marktkapitalisierung:
$987.43M
Einnahmen:
$62.04M
Nettoeinkommen (Verlust:
$-533.34M
KGV:
-1.7092
EPS:
-3.92
Netto-Cashflow:
$-473.07M
1W Leistung:
-3.32%
1M Leistung:
-17.39%
6M Leistung:
-11.02%
1J Leistung:
-33.86%
1-Tages-Spanne:
Value
$6.515
$6.71
1-Wochen-Bereich:
Value
$6.40
$7.22
52-Wochen-Spanne:
Value
$6.40
$14.45

Vir Biotechnology Inc Stock (VIR) Company Profile

Name
Firmenname
Vir Biotechnology Inc
Name
Telefon
415-906-4324
Name
Adresse
1800 OWENS STREET, SAN FRANCISCO, CA
Name
Mitarbeiter
0
Name
Twitter
@Vir_Biotech
Name
Nächster Verdiensttermin
2024-10-31
Name
Neueste SEC-Einreichungen
Name
VIR's Discussions on Twitter

Vergleichen Sie VIR mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
VIR
Vir Biotechnology Inc
6.70 987.43M 62.04M -533.34M -473.07M -3.92
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
492.69 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
637.36 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
589.15 35.93B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
268.46 34.75B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
267.39 28.24B 3.81B -644.79M -669.77M -6.24

Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-01-29 Herabstufung JP Morgan Overweight → Neutral
2023-09-08 Herabstufung BofA Securities Buy → Neutral
2023-03-06 Hochstufung JP Morgan Neutral → Overweight
2023-02-21 Hochstufung Goldman Neutral → Buy
2023-01-27 Hochstufung Morgan Stanley Underweight → Equal-Weight
2022-09-14 Eingeleitet SVB Leerink Outperform
2022-09-09 Eingeleitet Morgan Stanley Underweight
2022-03-03 Hochstufung Robert W. Baird Underperform → Neutral
2021-12-21 Herabstufung Robert W. Baird Neutral → Underperform
2021-10-25 Hochstufung JP Morgan Underweight → Neutral
2021-09-22 Herabstufung Goldman Buy → Neutral
2021-06-04 Fortgesetzt Robert W. Baird Neutral
2021-01-27 Herabstufung JP Morgan Neutral → Underweight
2021-01-20 Bestätigt H.C. Wainwright Buy
2020-10-05 Eingeleitet BofA Securities Buy
2020-09-14 Hochstufung Goldman Neutral → Buy
2020-09-11 Hochstufung JP Morgan Underweight → Neutral
2020-08-20 Eingeleitet Needham Buy
2020-03-19 Herabstufung JP Morgan Neutral → Underweight
2020-03-13 Herabstufung Goldman Buy → Neutral
2020-02-27 Herabstufung Robert W. Baird Neutral → Underperform
2020-02-04 Herabstufung JP Morgan Overweight → Neutral
2019-11-14 Eingeleitet Robert W. Baird Neutral
2019-11-05 Eingeleitet Barclays Overweight
2019-11-05 Eingeleitet Cowen Outperform
2019-11-05 Eingeleitet Goldman Buy
2019-11-05 Eingeleitet JP Morgan Overweight
Alle ansehen

Vir Biotechnology Inc Aktie (VIR) Neueste Nachrichten

pulisher
Mar 28, 2025

Vir Biotechnology, Inc. (NASDAQ:VIR) is favoured by institutional owners who hold 53% of the company - Yahoo Finance

Mar 28, 2025
pulisher
Mar 26, 2025

Vir Biotechnology stock hits 52-week low at $6.54 By Investing.com - Investing.com South Africa

Mar 26, 2025
pulisher
Mar 26, 2025

Vir Biotechnology stock hits 52-week low at $6.54 - Investing.com India

Mar 26, 2025
pulisher
Mar 24, 2025

(VIR) Trading Advice - Stock Traders Daily

Mar 24, 2025
pulisher
Mar 21, 2025

Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results - Quantisnow

Mar 21, 2025
pulisher
Mar 13, 2025

(VIR) Trading Signals - Stock Traders Daily

Mar 13, 2025
pulisher
Mar 13, 2025

Morgan Stanley maintains $20 target on Vir Biotechnology stock By Investing.com - Investing.com Canada

Mar 13, 2025
pulisher
Mar 13, 2025

Morgan Stanley maintains $20 target on Vir Biotechnology stock - Investing.com India

Mar 13, 2025
pulisher
Mar 13, 2025

Vir Biotechnology enrolls first patient in late-stage study of its treatment for severe liver infection - Marketscreener.com

Mar 13, 2025
pulisher
Mar 13, 2025

Vir Biotechnology Enrolls First Patient in Phase 3 Chronic Hepatitis Delta Trial -March 13, 2025 at 08:30 am EDT - Marketscreener.com

Mar 13, 2025
pulisher
Mar 13, 2025

Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta - Business Wire

Mar 13, 2025
pulisher
Mar 11, 2025

Insider Sell: Vicki Sato Sells Shares of Vir Biotechnology Inc (VIR) - GuruFocus.com

Mar 11, 2025
pulisher
Mar 11, 2025

SBI Securities Co. Ltd. Invests $60,000 in Vir Biotechnology, Inc. (NASDAQ:VIR) - Defense World

Mar 11, 2025
pulisher
Mar 07, 2025

Brokerages Set Vir Biotechnology, Inc. (NASDAQ:VIR) Price Target at $35.67 - Defense World

Mar 07, 2025
pulisher
Mar 05, 2025

Vir Biotechnology price target raised to $14 from $10 at JPMorgan - MSN

Mar 05, 2025
pulisher
Mar 05, 2025

Principal Financial Group Inc. Has $3.28 Million Stake in Vir Biotechnology, Inc. (NASDAQ:VIR) - Defense World

Mar 05, 2025
pulisher
Mar 05, 2025

Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Purchased by New York State Common Retirement Fund - Defense World

Mar 05, 2025
pulisher
Mar 05, 2025

Rhumbline Advisers Has $1.74 Million Stock Position in Vir Biotechnology, Inc. (NASDAQ:VIR) - Defense World

Mar 05, 2025
pulisher
Mar 04, 2025

Vir Biotechnology: Catalysts Ahead In Hepatitis And Oncology (NASDAQ:VIR) - Seeking Alpha

Mar 04, 2025
pulisher
Mar 03, 2025

Vir Biotechnology's (VIR) Buy Rating Reiterated at Needham & Company LLC - MarketBeat

Mar 03, 2025
pulisher
Mar 03, 2025

What is HC Wainwright’s Forecast for VIR Q1 Earnings? - Defense World

Mar 03, 2025
pulisher
Mar 02, 2025

(VIR) On The My Stocks Page - Stock Traders Daily

Mar 02, 2025
pulisher
Mar 02, 2025

HC Wainwright Reaffirms “Buy” Rating for Vir Biotechnology (NASDAQ:VIR) - Defense World

Mar 02, 2025
pulisher
Mar 02, 2025

Vir Biotechnology’s Strategic Advancements and Financial Health Justify Buy Rating - TipRanks

Mar 02, 2025
pulisher
Mar 02, 2025

Vir Biotechnology (NASDAQ:VIR) Stock Price Expected to Rise, Barclays Analyst Says - Defense World

Mar 02, 2025
pulisher
Mar 01, 2025

Analysts Have Lowered Expectations For Vir Biotechnology, Inc. (NASDAQ:VIR) After Its Latest Results - Yahoo Canada Finance

Mar 01, 2025
pulisher
Feb 28, 2025

7 Analysts Have This To Say About Vir Biotechnology - Benzinga

Feb 28, 2025
pulisher
Feb 28, 2025

Decoding Vir Biotechnology Inc (VIR): A Strategic SWOT Insight - GuruFocus.com

Feb 28, 2025
pulisher
Feb 27, 2025

Vir Biotechnology’s Transformative Year: Earnings Call Insights - TipRanks

Feb 27, 2025
pulisher
Feb 27, 2025

Vir Biotechnology Becomes Oversold (VIR) - Nasdaq

Feb 27, 2025
pulisher
Feb 27, 2025

Vir Biotechnology EVP vanina de Verneuil sells $67,402 in stock By Investing.com - Investing.com Canada

Feb 27, 2025
pulisher
Feb 27, 2025

Vir Biotechnology EVP vanina de Verneuil sells $67,402 in stock - Investing.com India

Feb 27, 2025
pulisher
Feb 27, 2025

Vir Biotechnology, Inc. (NASDAQ:VIR) Q4 2024 Earnings Call Transcript - Insider Monkey

Feb 27, 2025
pulisher
Feb 27, 2025

Promising Oncology Developments and Strong Financial Outlook Support Buy Rating for Vir Biotechnology - TipRanks

Feb 27, 2025
pulisher
Feb 27, 2025

Vir Biotechnology’s Promising Pipeline and Strong Financial Position Justify Buy Rating - TipRanks

Feb 27, 2025
pulisher
Feb 27, 2025

Vir Biotechnology: Balancing Long-term Potential with Near-term Uncertainty – A Hold Rating Analysis - TipRanks

Feb 27, 2025
pulisher
Feb 27, 2025

Vir Biotechnology, Inc. SEC 10-K Report - TradingView

Feb 27, 2025
pulisher
Feb 27, 2025

Hansoh ends collaboration with Silence; Vir hunts for HBV drug partner - Endpoints News

Feb 27, 2025
pulisher
Feb 27, 2025

Vir Biotechnology Inc (VIR) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ... - Yahoo Finance

Feb 27, 2025
pulisher
Feb 27, 2025

Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Lags Revenue Estimates - MSN

Feb 27, 2025
pulisher
Feb 27, 2025

Vir Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com

Feb 27, 2025
pulisher
Feb 27, 2025

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results - BioSpace

Feb 27, 2025
pulisher
Feb 26, 2025

Vir Biotechnology Reports 2024 Financial Results and Strategic Advances - TipRanks

Feb 26, 2025
pulisher
Feb 26, 2025

Vir Biotechnology: Strong Financial Position and Promising Pipeline Justify Buy Rating - TipRanks

Feb 26, 2025
pulisher
Feb 26, 2025

Earnings call transcript: Vir Biotech beats Q4 2024 forecasts, stock rises - Investing.com India

Feb 26, 2025
pulisher
Feb 26, 2025

Vir Biotechnology Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Feb 26, 2025
pulisher
Feb 26, 2025

Vir Biotechnology reports Q4 EPS (76c), consensus (87c) - TipRanks

Feb 26, 2025
pulisher
Feb 26, 2025

Vir Biotechnology Inc. (VIR) Tops Q4 EPS by 11c - StreetInsider.com

Feb 26, 2025
pulisher
Feb 25, 2025

Vir Biotechnology CEO sells $152,407 in stock By Investing.com - Investing.com South Africa

Feb 25, 2025
pulisher
Feb 25, 2025

Vir Biotechnology's SVP sells shares worth $14,766 By Investing.com - Investing.com Canada

Feb 25, 2025
pulisher
Feb 25, 2025

Vir Biotechnology EVP vanina de Verneuil sells $48,590 in shares By Investing.com - Investing.com Australia

Feb 25, 2025

Finanzdaten der Vir Biotechnology Inc-Aktie (VIR)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$77.99
price up icon 0.39%
$306.97
price down icon 0.34%
$31.37
price down icon 0.88%
$20.32
price down icon 1.36%
$94.95
price down icon 0.47%
biotechnology ONC
$267.39
price up icon 1.82%
Kapitalisierung:     |  Volumen (24h):